CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production
- Parties intend to jointly enable AAV production in CEVEC’s CAP®GT cells in combination with PlasmidFactory’s broad AAV serotype plasmid portfolio
- Collaboration will significantly increase the value of CAP®GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications
Cologne, Germany, May 11, 2017
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will collaborate with PlasmidFactory, the leading contract manufacturer and service provider for plasmid and minicircle DNA.
The collaboration will allow CEVEC access to PlasmidFactory’s broad portfolio of AAV helper and packaging plasmids of the pDG family. The pDG plasmids support transfection of cells for AAV production, where the essential viral helper and packaging functions are located on only one plasmid, greatly facilitating the production of high AAV titers.